Condition: Non Muscle Invasive Bladder Cancer · Sponsor: CG Oncology, Inc.
To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscle invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or without Ta/T1 papillary disease.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of California - San Diego | La Jolla, California, United States | — |
| University of California - Irvine | Orange, California, United States | — |
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| Northwestern University | Tampa, Florida, United States | — |
| Johns Hopkins Medical Institution | Baltimore, Maryland, United States | — |
| Chesapeake Urology | Hanover, Maryland, United States | — |
| Mayo Clinic - Rochester | Rochester, Minnesota, United States | — |
| New York University | New York, New York, United States | — |
| SUNY Upstate Medical University | Syracuse, New York, United States | — |
| Ohio State University | Columbus, Ohio, United States | — |
| Keystone Urology Specialists | Lancaster, Pennsylvania, United States | — |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | — |
+ 7 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04387461